CD22: a regulator of innate and adaptive B cell responses and autoimmunity
EA Clark, NV Giltiay - Frontiers in immunology, 2018 - frontiersin.org
EA Clark, NV Giltiay
Frontiers in immunology, 2018•frontiersin.orgCD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized
over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston.
Several excellent reviews have detailed CD22 functions, CD22-regulated signaling
pathways and B cell subsets regulated by CD22 or Siglec G (–). This review is an attempt to
highlight recent and possibly forgotten findings. We also describe the role of CD22 in
autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment …
over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston.
Several excellent reviews have detailed CD22 functions, CD22-regulated signaling
pathways and B cell subsets regulated by CD22 or Siglec G (–). This review is an attempt to
highlight recent and possibly forgotten findings. We also describe the role of CD22 in
autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment …
CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston . Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets regulated by CD22 or Siglec G (–). This review is an attempt to highlight recent and possibly forgotten findings. We also describe the role of CD22 in autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE).
Frontiers